Moderna Inc (MRNA) 13F Positioning & Ownership Changes (Q2 2026)

MRNA ranks #636 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

MRNA is a disclosed holding of Baillie Gifford (Baillie Gifford & Co.), one of the tracked superinvestors on AlphaSMO — it makes up 1.2% of that fund's own 13F portfolio.

MRNA is a top-conviction position for Theleme Partners LLP — at 33.5% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in MRNA belongs to FMR LLC, but the position matters far more to Theleme Partners LLP, who has 33.5% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Fidelity has added to its MRNA position for two straight quarters, increasing it by $2.8B to reach $3.6B today.

David Shaw has trimmed its MRNA position for two straight quarters, cutting it by $128.4M while still holding $200.7M.

MRNA is down 5.8% today, but institutions show net buying of $1.8B this quarter — a divergence between today's price move and the underlying institutional flow.

MRNA reported a net loss of $3.2B over the trailing twelve months.

• Not yet profitable — net loss of $3.2B over the trailing twelve months
• Revenue declined 27.6% year over year
• Net income declined year over year, from -$2.9B to -$3.2B
• Operating cash flow was negative, using $1.9B in cash
• Current ratio of 3.29x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.43x equity — within a conventional range